Wearable sensors for prediction of intraamniotic infection in women with preterm premature rupture of membranes: a prospective proof of principle study.
Romana Brun, Julia Girsberger, Martina Rothenbühler...
https://pubmed.ncbi.nlm.nih.gov/36098832/Actively Recruiting
Led by The Central and Eastern European Gynecologic Oncology Group · Updated on 2026-06-18
138
Participants Needed
3
Research Sites
34 weeks
Total Duration
Researchers are studying whether using a lab test called interleukin-6 IL-6 from amniotic fluid can help guide antibiotic and steroid treatment to safely prolong pregnancy in people who experience preterm premature rupture of membranes pPROM. This condition causes the water to break too early before 37 weeks, increasing risks of infection and early birth. The study aims to see if tailoring treatment based on IL-6 can help pregnancies last more than 7 days after pPROM and improve health outcomes for both parent and baby. Participants will be randomly assigned to one of two groups. One group receives treatment tailored to IL-6 levels from weekly amniocentesis tests, where steroids and antibiotics are adjusted based on the lab results. The other group receives standard care with antibiotics and steroids given right after diagnosis. The study also includes neuroprotection treatment for imminent preterm birth before 32 weeks, with detailed antibiotic regimens and monitoring. Participants will undergo screening to confirm pPROM and eligibility, then receive hospital monitoring until delivery, including weekly amniocentesis if in the tailored group. After birth, follow-up lasts 6 months to track health outcomes for both parent and child. Researchers will measure how long the pregnancy lasts after membrane rupture, rates of infection, and short-term maternal and neonatal health outcomes to evaluate the treatment approaches.
CONDITIONS
TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden
K
Katerina Mackova, MD, PhD, PhD
M
Martina Boricnova, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Central and Eastern European Gynecologic Oncology Group
Lead Sponsor
Brno University Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened to confirm preterm premature rupture of membranes and eligibility to join the trial.
1 screening visit
Duration - Up to 98 days or until delivery
Participants are randomly assigned to either tailored treatment guided by IL-6 levels with weekly amniocentesis or to standard care with fixed antibiotic and steroid regimens. Monitoring occurs in the hospital until delivery.
Regular hospital check-ups and weekly amniocentesis if in tailored group
Duration - 6 months
Health outcomes for both parent and baby are followed for 6 months after birth to track recovery and well-being.
Periodic follow-up visits after birth
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Romana Brun, Julia Girsberger, Martina Rothenbühler...
https://pubmed.ncbi.nlm.nih.gov/36098832/Diana M Bond, Philippa Middleton, Kate M Levett...
https://pubmed.ncbi.nlm.nih.gov/28257562/Aditi Garg, Arpita Jaiswal
https://pubmed.ncbi.nlm.nih.gov/37155446/Lillian B Boettcher, Erin A S Clark
https://pubmed.ncbi.nlm.nih.gov/33121652/Gerard H A Visser, Trude Thommesen, Gian Carlo Di Renzo...
https://pubmed.ncbi.nlm.nih.gov/33128246/Roberto Romero, Jimmy Espinoza, Luís F Gonçalves...
https://pubmed.ncbi.nlm.nih.gov/17205421/Eunjung Jung, Roberto Romero, Lami Yeo...
https://pubmed.ncbi.nlm.nih.gov/33164775/Robert L Goldenberg, Jennifer F Culhane, Jay D Iams...
https://pubmed.ncbi.nlm.nih.gov/18177778/Philippa Middleton, Emily Shepherd, Vicki Flenady...
https://pubmed.ncbi.nlm.nih.gov/28050900/The Central and Eastern European Gynecologic Oncology Group
Lead Sponsor
Brno University Hospital
Collaborating Sponsor